Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-17T18:02:09.585Z Has data issue: false hasContentIssue false

17 - Prophylactic mastectomy in mutation carriers

Published online by Cambridge University Press:  24 August 2009

D. G. R. Evans
Affiliation:
St Mary's Hospital, Manchester, UK
F. I. Lalloo
Affiliation:
St Mary's Hospital, Manchester, UK
A. D. Baildam
Affiliation:
Withington Hospital, Manchester, UK
Patrick J. Morrison
Affiliation:
Belfast City Hospital, Belfast
Shirley V. Hodgson
Affiliation:
Guy's Hospital, London
Neva E. Haites
Affiliation:
University of Aberdeen
Get access

Summary

Introduction

Management options available for women at high lifetime risk of breast cancer due to their family history, or carriage of a mutation in BRCA1/2 (which confer a lifetime risk of breast cancer of 85% (Ford et al., 1994; Wooster et al., 1994) are limited. Screening with mammography or even magnetic resonance imaging (MRI) is one option, and this can be combined with entering trials of chemo-prevention. However, many women are now seriously considering or undertaking prophylactic mastectomy if found to be mutation carriers for BRCA1 or BRCA2. The efficacy of surgical procedures to reduce the risk of breast cancer is controversial (Goodnight et al., 1984; Zeigler and Kroll, 1991), although it would appear that the residual risk of breast cancer is dependent upon the amount of remaining breast tissue following the surgical procedure. Recent work suggests that more women than previously are considering prophylactic mastectomy (JW et al., 1996; Lynch et al., 1997) and that protocols should be in place to deal with these requests. It has been suggested that surgery will increase life expectancy in BRCA1 or BRCA2 mutation carriers (Schrag et al., 1997). A recent study by Hartmann et al., (1999) has demonstrated that women with a high risk of breast cancer can significantly reduce the incidence of the disease with prophylactic surgery. However, the level of reduction in those at highest risk (BRCA1/BRCA2 carriers) is still unclear.

Type
Chapter
Information
Familial Breast and Ovarian Cancer
Genetics, Screening and Management
, pp. 286 - 294
Publisher: Cambridge University Press
Print publication year: 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×